A MELAS Patient Developing Fatal Acute Renal Failure with Lactic Acidosis and Rhabdomyolysis

Hisashi Ito¹, Shigeru Fukutake¹, Sanae Odake², Riki Okeda¹,
Osamu Tokunaga¹ and Tetsumasa Kamei¹

Abstract:
We herein present a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS), who developed serious acute renal failure with lactic acidosis, followed by rhabdomyolysis. Despite receiving intensive care, he suffered multiple cardiopulmonary arrests and died 10 days after presentation due to a sudden deterioration of his symptoms. Renal pathology revealed diffuse tubular necrosis with interstitial edema and tubular dilatation on light microscopy, and a severe degeneration of intracellular organelles on electron microscopy. These pathological findings could have resulted from multiple cardiopulmonary arrests; however, we must be aware of the extremely rare but sudden occurrence of these fatal conditions in MELAS patients.

Key words: acute renal failure, lactic acidosis, rhabdomyolysis

Introduction
Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a multi-organ disorder. Regarding renal involvement in MELAS patients, it tends to be chronic, but it is rarer than in other organ abnormalities. Such renal involvement can lead to a serious condition (1, 2); however, the trigger such involvement remains to be elucidated. We herein report a MELAS patient who suddenly developed acute renal failure with severe lactic acidosis, followed by rhabdomyolysis.

Case Report
A 30-year old man developed headache, vomiting, and aphasia at the age of 25. He had experienced right hearing disturbance since the age of 22; however, he had no past history of renal failure, rhabdomyolysis, or any cardiac events. His mother was diagnosed to have MELAS with A 3243G mutations in mitochondrial DNA (heteroplasmy 5%). The findings of a routine blood examination and blood gas analysis were normal; however, the serum lactate level was 25.0 mg/dL (normal range: 4.2-17.0 mg/dL), pyruvate level was 1.4 mg/dL (normal range: 0.3-0.9 mg/dL), and the ratio of lactate / pyruvate was 17.9 (normal range: <10). In addition, the cerebrospinal fluid lactate level was 48.6 mg/dL (normal range: 9-16 mg/dL), pyruvate level was 1.6 mg/dL (normal range: 0.6-1.2 mg/dL), and the ratio of lactate / pyruvate was 30.4. Diffusion-weighted (DW) brain MR imaging demonstrated a large abnormal high-signal lesion in the left temporal, parietal, and occipital lobes. ECD-SPECT showed a decrease in the tracer uptake of these lesions. Conventional Hematoxylin and Eosin staining and Gomori-Trichrome staining of biopsied biceps revealed a variation in the fiber size and many ragged-red fibers. Neither necrotic nor regenerating fibers were observed. We diagnosed the patient to have MELAS based on 3243G mutations in mitochondrial DNA (heteroplasmy 37%). As taurine had not been approved in Japan at that time (3), we administered 30 g of intravenous L-arginine daily (4). The administration of L-arginine was approved by the Review Board of Shonan Fujisawa Tokushukai Hospital. The patient provided written informed consent in accordance with the Declaration of Hel-
sinki. The patient improved gradually, and we thus continued 12 g of oral L-arginine daily.

At 30 years of age, he developed a headache, vomiting, and apraxia. A routine blood examination including a blood gas analysis and BNP showed normal findings; however, the serum lactate and pyruvate levels were 25.2 mg/dL and 1.2 mg/dL (the ratio of lactate / pyruvate was 21.0). Although ECG was normal, echocardiogram showed ventricular wall thickening, especially in the posterior wall (EF was 66.0%). Brain MR imaging revealed a high-signal in DW and low-signal in apparent diffusion coefficient (ADC) in the right temporal and parietal lobes (Fig. 1A). We resumed the drip infusion of L-arginine (30 g per day). At 38 days of admission, most of the abnormal MR signals had disappeared (Fig. 1B) and a routine blood examination revealed mild BUN elevation (37.3 mg/dL) with normal creatinine and electrolyte levels. His vital signs were normal, and we observed neither any signs of infection nor seizures. No mitochondrial toxins, including aminoglycoside, valproic acid, or dichloroacetate, were administered. However, he suffered cardiopulmonary arrest suddenly at night on the following day. The BUN, creatinine, potassium, and BNP levels were elevated to 100.2 mg/dL, 4.42 mg/dL, 7.4 mEq/L, and 79.4 mg/dL, respectively. Severe metabolic acidosis with an increased anion gap was revealed (pH 6.81, PCO₂ 50.6 mmHg, PO₂ 30.4 mmHg, HCO₃ 7.5 mmol/L, and BE -30.3 mEq/L). The serum lactate and pyruvate levels were 249.6 mg/dL and 7.7 mg/dL (the ratio of lactate / pyruvate was 32.4). Non-contrast abdominal CT imaging demonstrated neither any obstruction of the gastrointestinal tract nor hyperdensity in the portal vein. In addition, we did not detect any urinary tract obstruction. We successfully resuscitated the patient with cardiopulmonary resuscitation with the rapid intravenous infusion of a large quantity of bicarbonate; however, severe acute renal dysfunction with lactic acidosis continued and severe rhabdomyolysis followed (CK 153,293 IU/L, AST 2,551 IU/L, LDH 6,897 IU/L). Despite receiving intensive care, including percutaneous cardiopulmonary support and continuous hemodialysis, he suffered multiple cardiopulmonary arrests and died 10 days later due to a sudden deterioration of his symptoms.

**Autopsy findings**

We performed an autopsy limited to the abdominal organs. The prefixed kidneys weighed 205 g (right) and 240 g (left). There were no marked abnormalities in the liver, pancreas, or gastrointestinal tract macroscopically. Light microscopy of the kidney revealed no abnormality in the arterial capillaries; however, severe tubular necrosis with interstitial edema and tubular dilatation were observed (Fig. 2A). In addition, mild interstitial fibrosis was observed in the pancreas. Electron microscopy of the kidney revealed the severe degeneration of the intracellular organelles (Fig. 2B).
MELAS is characterized by the mitochondrial dysfunction of multiple organs. The commonly affected extraneuromuscular organs are the heart, pancreas, and hematopoietic system. On the other hand, the liver, endocrine glands, and kidney are less often affected (1). Most renal involvements in MELAS tend to be associated with chronic renal failure (5). We could find only a small number of reports on acute renal failure associated with MELAS (6-8). Acute exacerbations of MELAS could be triggered by febrile illness, mitochondrial toxins, cigarettes, and alcohol (9). Two patients, who developed acute renal failure and rhabdomyolysis after alcohol consumption, were reported previously (7, 8); however, we could not identify exacerbation factors in our case.

The renal pathology in MELAS has been reported as the dilatation of the renal tubules (10), granular swollen tubular epithelial cells (11), and global or focal-segmental glomerulosclerosis (10-13). Although this patient demonstrated severe tubular pathology, we could not identify any arterial capillaries changes. Yanagihara et al. suggested that not only hemodynamic insufficiency due to vascular changes but mitochondrial damage due to MELAS could cause renal involvement (5). As we did not observe any vascular changes, intrinsic mitochondrial dysfunction might have been the trigger of a sudden deterioration in this case. However, electron microscopy did not reveal the accumulation of any abnormal mitochondria and it indicated that the renal tubular pathology might have resulted from multiple cardiopulmonary arrests.

Therefore, we could not clarify the trigger of the sudden development of fatal acute renal failure and rhabdomyolysis in this patient. However, this patient alerts us to the extremely rare but sudden development of these fatal conditions during the course of MELAS, despite obtaining an improvement in cerebral lesion. As there might be some unknown triggers of acute renal failure and rhabdomyolysis, further investigation with more MELAS patients is necessary.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We gratefully thank Dr. Minoru Shimizu†, Dr. Hirohito Shimizu‡, Dr. Shigeto Horiuchi*, Dr. Makoto Hibino†, Dr. Shinji Tanaka**, Dr. Shota Akabane***, Dr. Daisuke Yuji****, Dr. Ikuo Katayama***** Ms. Yuka Aman******, and Ms. Fujiko Kato******* (Department of *Hepato-Gastroenterology, **Pulmonary Medicine, ***Cardiovascular Medicine, ****General Surgery, *****Cardiovascular Surgery, and ******Nursing, Shonan Fujisawa Tokushukai Hospital) for their supports in intensive care. Additionally, we also thank Dr. Terunori Sano, Dr. Yuko Saito, and Mr. Masahiro Sakamoto (Department of Pathology and Laboratory Medicine, National Center Hospital, National Center of Neurology and Psychiatry) for their assistance with the electron microscopic study.

References

1. Sproule DM, Kaufmann P. Mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes: basic concepts, clinical phenotype, and therapeutic management of MELAS syndrome. Ann NY Acad Sci 1142: 133-158, 2008.
2. Klopstock T, Jakob M, Gasser T. Age and cause of death in mitochondrial diseases. Neurology 53: 855-857, 1999.
3. Ohsawa Y, Hagiwara H, Nishimatsu S, et al. Taurine supplementation for prevention of stroke-like episodes in MELAS: A multicentre, open-label, 52-week phase III trial. J Neurol Neurosurg Psychiatry 90: 529-536, 2019.
4. Koenig MK, Emrick L, Karaa A, et al. Recommendations for the management of stroke-like episodes in patients with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes. JAMA Neurol 73: 591-594, 2016.
5. Yanagihara C, Oyama A, Tanaka M, Nakaji K, Nishimura Y. An autopsy case of mitochondrial encephalomyopathy with lactic aci-
dosis and stroke-like episodes syndrome with chronic renal failure. Intern Med 40: 662-665, 2001.

6. Hsieh F, Gohh P, Dworkin L. Acute renal failure and the MELAS syndrome, a mitochondrial encephalomyopathy. J Am Soc Nephrol 7: 647-652, 1996.

7. Shinde A, Nakano S, Taguchi Y, Kagawa D, Akiguchi I. A patient of MELAS with 3271 mutation with fatal outcome after alcohol intake. Clin Neurol 40: 561-565, 2000.

8. Yokoyama J, Yamaguchi H, Shigeto H, Uchiimi T, Murai H, Kira J. A case of rhabdomyolysis after status epilepticus without stroke-like episodes in mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes. Clin Neurol 56: 204-207, 2016.

9. El-Hattab AW, Almannai M, Scaglia F. MELAS. 2001 Feb 27 [Internet]. In: Adam MP, Ardinger HH, Pagon RA, et al., Eds. GeneReviews®, Seattle (WA): University of Washington, Seattle, 1993-2020 [updated 2018 Nov 29]

10. Ban S, Mori N, Saito K, Mizukami K, Suzuki T, Shiraishi H. An autopsy case of mitochondrial encephalomyopathy (MELAS) with special reference to extra-neuromuscular abnormalities. Acta Pathol Jpn 42: 818-825, 1992.

11. Motoda A, Kurashige T, Sugiura T, et al. A case of MELAS with G13513A mutation presenting with chronic kidney disease long before stroke-like episodes. Clin Neurol 53: 446-451, 2013.

12. Kurogouchi F, Oguchi T, Mawatari E, et al. A case of mitochondrial cytopathy with a typical point mutation for MELAS, presenting with severe focal-segmental glomerulosclerosis as main clinical manifestation. Am J Nephrol 18: 551-556, 1998.

13. Seidowsky A, Hoffmann M, Glowacki F, et al. Renal involvement in MELAS syndrome - a series of 5 cases and review of the literature. Clin Nephrol 80: 456-463, 2013.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© The Japanese Society of Internal Medicine

Intern Med Advance Publication